Introduction {#s1}
============

Acute ischemic stroke (IS) is a major cause of mortality and disability worldwide, and the incidence is increasing ([@B1]). Despite advances in the cause and acute treatment of ischemic stroke, its exact pathophysiologic mechanisms are still not completely understood. However, accumulating evidence has shown that long non-coding RNAs (LncRNAs) play critical roles in the pathogenesis of rodent ([@B2], [@B3]) and human ischemic stroke ([@B4]).

LncRNAs, which are defined as transcripts of more than 200 nucleotides that are not translated into proteins, have historically been regarded as junk DNA. However, with the development of high-throughput technologies, recent studies have revealed that many non-coding RNAs play critical roles in cellular homeostasis ([@B5], [@B6]). The functions of LncRNAs have been proposed to include organization of nuclear domains, cis-, or transregulation of transcription, regulation of proteins or RNA molecules, and even encoding of small proteins ([@B7]--[@B9]). Moreover, several LncRNAs have been shown to play roles in animal models of stroke and oxygen-glucose deprivation (OGD) cell models ([@B2], [@B10]). Using genome-wide RNA-seq, Bhattarai et al. found that transient focal ischemia induces widespread changes in the expression of LncRNAs in the mouse cortex, and a plethora of those LncRNAs were unannotated ([@B11]). After exposure to OGD, which mimics ischemic conditions *in vitro*, the expression of LncRNAs changed significantly in mouse brain microvascular endothelial cells ([@B12]). As there is a species difference between rodents and humans, the lncRNA profile after ischemic stroke in patients definitely needs to be investigated. However, recent studies on the issue focused only on a limited number of LncRNAs, such as H19 ([@B10]) and antisense non-coding RNA in the INK4 locus (ANRIL) ([@B13]). While a large number of LncRNAs remain undiscovered in human ischemic stroke, the functions of most LncRNAs have not yet been elucidated ([@B6], [@B14]). Thus, we used next-generation sequencing technology to characterize the systemic gene expression of peripheral blood mononuclear cells (PBMCs) in ischemic stroke patients.

In addition, ischemic stroke induces profound effects on the peripheral immune system, the state of which changes from activation to systemic immunosuppression during the transition from the acute to subacute stage ([@B15]). However, why and how the peripheral immune system participates in stroke pathology and whether LncRNAs take part in stroke pathology are largely unknown. To address this gap in knowledge, in this work, we used unbiased high-throughput RNA-seq to determine the genome-wide expression of LncRNAs in PBMCs from patients following acute ischemic stroke and investigated changes in lncRNA expression over the acute to subacute transition phase of ischemic stroke.

Materials and Methods {#s2}
=====================

Study Subjects
--------------

Acute ischemic stroke patients and control subjects were recruited between 2015 and 2016 from Tianjin Medical University General Hospital, China. The present study was approved by the Ethics Committee of Tianjin Medical University General Hospital, and written informed consent was provided by the participants or their proxy. We enrolled 5 patients (10 samples) between the ages of 50 and 75 years with first-ever acute ischemic stroke defined as acute lesion on diffusion-weighted image (DWI), corresponding acute neurological deficit and anterior or middle cerebral artery occlusion proved by magnetic resonance angiography (MRA), who arrived at the hospital between 4.5 to 24 h after symptom onset ([Table 1](#T1){ref-type="table"}). The criteria for exclusion included hemorrhagic stroke; hemorrhagic transformation or recurrent stroke; myocardial infarction, atrial fibrillation and other cardiovascular diseases; treatments with thrombolytic or anticoagulants; evidence of other diseases of the central nervous system; tumor(s); the presence of recent infection; immune diseases; concomitant use of antineoplastic, immunosuppressive or immune-modulating therapies; abnormal renal or liver function; blood disorders; or diabetes mellitus. The control group consisted of 5 healthy adults matched for age, sex and vascular risk factors, including body mass index, hypertension, and hyperlipidemia.

###### 

Clinical characteristics of ischemic stroke patients and vascular risk factor-matched controls.

                                             **IS patients (*n* = 5)**   **Controls (*n* = 5)**   ***P*****-value**
  ------------------------------------------ --------------------------- ------------------------ -------------------
  Mean age (SD), yr                          61 ± 11.3                   59 ± 6.2                 0.795
  Sex, male (%)                              4 (80)                      4 (80)                   1.000
  Body mass index (BMI)                      25 ± 0.8                    24 ± 1.1                 0.642
  **MEDICAL HISTORY**                                                                             
  Hypertension, *n* (%)                      2 (40)                      3 (60)                   1.000
  Hyperlipidemia, *n* (%)                    4 (80)                      2 (40)                   0.521
  Current smoking, *n* (%)                   4 (80)                      3 (60)                   0.782
  **MEDICATION, N (%)**                                                                           
  Antiplatelet agent                         1 (20)                      2 (40)                   0.660
  Median NIHSS score at baseline (IQR)       12 (6--21)                  0                        
  **OCCLUSION SITE, N (%)**                                                                       
  Terminal internal carotid artery           1 (20)                      0                        
  First segment of middle cerebral artery    3 (60)                      0                        
  Second segment of middle cerebral artery   1 (20)                      0                        

*IS, ischemic stroke; NIHSS, National Institutes of Health Stroke Scale; IQR, interquartile range*.

*Hypertension was defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg or use of antihypertensive agents; Hyperlipidemia was defined as a total serum cholesterol level \> 5.72 mmol/L and/or triglycerides \>1.7 mmol/L or use of antihyperlipidemic medication*.

Blood Collection and RNA Extraction
-----------------------------------

Blood was collected within 24 h and 7 days after symptom onset. For control samples, blood was collected only once. Blood samples were obtained in PaxGene tubes containing a reagent to stabilize RNA. Total RNA was extracted and purified from PBMCs using TRIzol reagent (Invitrogen, Grand Island, USA) according to the manufacturer\'s standard protocol. The concentration of RNA was determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, USA), and quality assessment was made by an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany). No samples were removed from the RNA-seq analysis due to disqualification of the blood sample or a low total RNA yield.

Library Preparation for lncRNA Sequencing and Data Analysis
-----------------------------------------------------------

RNA extracted by TRIzol reagent with RIN\>8.0 was utilized to construct a ribosomal RNA (rRNA) depletion library \[VAHTSTM Total RNA-seq (H/M/R)\], according to the manufacturer\'s recommendations. In this experiment, 15 samples from 10 individuals were used for pair-end RNA sequencing with Illumina HiSeq 4000 platform. Raw data of each samples obtained more than 10 G bases and Q30 were \>95% totally. Next, clean reads were obtained by removing the adaptor sequences, reads with \>5% ambiguous bases (noted as N) and low-quality reads containing more than 20 percent of bases with qualities of \<20 from raw data. Then, the clean data were mapped to the human genome (GRCh38 database, NCBI) utilizing HISAT2, and HTSeq was used to calculate the gene count of mRNA and lncRNA. RNA-seq data were analyzed by Novel Bioinformatics Company (Shanghai, China).

Prediction of Target Genes
--------------------------

The cis- and transregulatory effects of LncRNAs were used to target the positions of protein-coding genes and predict their functions. In the present study, protein-coding genes located within 10 kb upstream or downstream of the given LncRNAs were classified as LncRNAs of cis-regulated target genes. Furthermore, we analyzed the coexpression of LncRNAs and coding genes by calculating Pearson\'s correlation coefficient.

Differential Expression Analysis
--------------------------------

The EB-Seq algorithm was used to test the differential expression of both LncRNAs and coding genes among the groups ([@B16]). R programming was applied to analyze the lncRNA-gene pairs. The differentially expressed genes were chosen as follows: fold change \>2 or \<0.5; *P*-value \<0.05 and false discovery rate (FDR) \<0.05. Hierarchical clustering was performed based on the normalized expression of LncRNAs and mRNAs from all groups using Cluster 3.0. Heatmaps were completed with Java TreeView.

GO and KEGG Enrichment Analysis
-------------------------------

Gene ontology (GO) enrichment analysis and kyoto encyclopedia of genes and genomes (KEGG) pathway analysis were applied for functional annotation. The GO analysis was implemented with the UniProt and AmiGO databases (<http://www.uniprot.org> and <http://amigo1.geneontology.org/cgi-bin/amigo/go.cgi>). The KEGG database is the resource for understanding high-level functions and effects of biological systems (<http://www.genome.jp/kegg/>). Significance *P*-values were defined by Fisher\'s exact test, and FDR was calculated by the BH test. Differentially expressed genes were considered to be significantly enriched for GO and KEGG terms with *p* \< 0.05.

Coexpression Network Construction
---------------------------------

We constructed the lncRNA-mRNA coexpression network to identify the interactions among differentially expressed LncRNAs and mRNAs ([@B17]). We calculated Pearson\'s correlations and chose the significant correlation between each pair of genes to construct the network. In gene coexpression networks, we chose degree centrality to determine the relative importance of a gene within a network. Degree centrality is defined as the link numbers one node has with the other. Moreover, to locate core regulatory genes, k-cores in graph theory were introduced as a method of simplifying graph topology analysis. A k-core of a protein-protein interaction network usually contained cohesive groups of proteins ([@B18]).

Quantitative PCR Analysis
-------------------------

To verify the RNA-seq data, we randomly selected 6 differentially expressed LncRNAs and detected their expression changes by quantitative PCR (qPCR) (*n* = 10, 5 patients with acute ischemic stroke and 5 healthy controls). Total RNA was extracted from PBMCs with TRIzol® reagent (Invitrogen, USA) following the manufacturer\'s instructions. RNA quantity was determined with a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, USA), and quality assessment was made by an Agilent 2100 Bioanalyzer (Agilent, Waldbronn, Germany). The total RNA was then reverse transcribed to cDNA using EasyScript First-Strand cDNA synthesis SuperMix (Transgen, Beijing, China) according to the manufacturer\'s instructions. SYBR Green (Roche, Basel, Switzerland) was used for qPCR. β-Actin mRNA was used as an internal control. The results were analyzed according to the 2^−ΔΔCt^ method. The 6 LncRNAs and qPCR primers are provided in [Table 2](#T2){ref-type="table"}. Statistical analysis was performed using Student\'s *t*-test, and *p* \< 0.05 was considered to indicate statistical significance.

###### 

List of primers for qRT-PCR.

  ---------------------------------------------------------------------------------------------
  **Name**    **Forward Primer (5^**′**^-3^**′**^)**   **Reverse Primer (5^**′**^-3^**′**^)**
  ----------- ---------------------------------------- ----------------------------------------
  β-Actin     CCAGGGCGTTATGGTAGGCA                     TTCCATATCGTCCCAGTTGGT

  SCARNA10    GGT CTG TAA TCT TGG TGG\                 AGG ACC CTT GGC CCT GAT\
              GCG                                      AC

  TERC        CAC TGC CAC CGC GAA\                     ACT CGC TCC GTT CCT CTT\
              GAG TTG                                  CCTG

  LINC01481   CGT CAC CGT CAC CTC CTG\                 GGC TAG AGC AAG TTC ACA\
              AGT AG                                   CGA CAC

  FLJ23867    TGA GGA GGC TTC TGC\                     ATA CCA AGG CTG CTG GAG\
              GAG ACC                                  AGG AG

  H3F3AP6     AGC TCC AGC CGA AGG\                     TCA CGG AGC GCC ACA\
              AGA AGG                                  GTA CC

  TNPO1P1     TGC CTA TCT TCA GTT GCC\                 ATG TTG CCT CCA AGT CCT\
              ACA GC                                   TCA GC
  ---------------------------------------------------------------------------------------------

Results {#s3}
=======

Clinical Characteristics of IS Patients
---------------------------------------

We collected 15 samples (10 ischemic stroke and 5 controls). The mean score on the National Institutes of Health Stroke Scale (NIHSS) was 12 ± 9, and the infarct volume was 42 ± 5 ml at inclusion (24 ± 0.6 h after ischemia). The mean time from stroke onset to blood collection was 24 ± 0.6 h and 7 ± 0.2 days. Baseline characteristics were generally balanced between the two groups ([Table 1](#T1){ref-type="table"}). Patients with acute ischemic stroke had an older age (61 vs. 59), a higher median body mass index (25 vs. 24) and hyperlipemia (4 vs. 2), although these potential differences were not statistically significant ([Table 1](#T1){ref-type="table"}).

Differentially Expressed LncRNAs and mRNAs in IS Patients
---------------------------------------------------------

Total RNA from PBMCs of all five patients (at two time points) and controls were isolated and sequenced. A total of 438 million (IS-24 h), 448 million (IS-7 d), and 433 million (control) raw reads were obtained by RNA-seq ([Table 3](#T3){ref-type="table"}). After quality control, approximately 415 million and 424 million clean reads were isolated from ischemic stroke patients at 24 h and 7 days, respectively, and 409 million clean reads were obtained for the control group. The sequence reads were used to map known human gene types. Approximately 86.0% (IS-24 h) and 88.9% (IS-7d) of the clean reads were uniquely mapped to the reference genome, and in the control group, approximately 91.3% of the clean reads were uniquely mapped to the reference human genome ([Table 3](#T3){ref-type="table"}).

###### 

Summary of sequence reads mapping to genome.

  **Subjects**   **Raw reads**   **Clean reads**   **Total mapped**   **Uniquely mapped**
  -------------- --------------- ----------------- ------------------ ---------------------
  IS 24h-1       93266260        88229464          85737538 (93.4%)   77314172 (84.2%)
  IS 24h-2       84579048        80308938          79940077 (96.0%)   72561277 (87.2%)
  IS 24h-3       85099148        80991756          80976131 (96.5%)   73478271 (87.5%)
  IS 24h-4       82115336        77887870          78022799 (96.3%)   70670320 (87.2%)
  IS 24h-5       93048884        88083076          88743881 (95.7%)   77803726 (83.9%)
  IS 7d-1        86821228        81949902          81737184 (97.3%)   76647999 (91.2%)
  IS 7d-2        101448746       96386482          95903673 (95.9%)   86618696 (86.6%)
  IS 7d-3        82956746        77636230          77461460 (96.4%)   71018180 (88.4%)
  IS 7d-4        87137944        82831000          81892575 (96.1%)   75828010 (89.0%)
  IS 7d-5        90385706        85835948          84945035 (96.3%)   78942332 (89.5%)
  Control-1      87788642        83192158          82064394 (96.6%)   77357888 (91.1%)
  Control-2      88253988        83340744          82096397 (96.7%)   77763616 (91.6%)
  Control-3      84166168        79853224          78060291 (95.7%)   73549421 (90.2%)
  Control-4      83464700        78827834          77872308 (97.0%)   74052126 (92.2%)
  Control-5      89547908        83945934          82706071 (96.7%)   78385062(91.6%)

*IS, ischemic stroke*.

To evaluate the consistency of the sample collection and investigate the transcriptomic relationship between the 24-h and 7-day time points in the stroke patients, we performed hierarchical clustering and principal component analysis (PCA) for these samples using RNA-seq data. Both analyses can provide an overview of the similarities and dissimilarities between samples. The expression level in each sample showed no differences in terms of reads per kilobase per million (RPKM) values ([Figure 1A](#F1){ref-type="fig"}). In the 3D-PCA plot, the PBMC samples from control subjects were grouped together ([Figure 1B](#F1){ref-type="fig"}), which was in agreement with the hierarchical clustering analysis. In ischemic stroke patients, the PBMC samples from the two time points were grouped together with slight variation, which is acceptable considering individual differences ([Figure 1B](#F1){ref-type="fig"}).

![RNA-seq analysis of mRNAs and LncRNAs in IS patients. **(A)** RPKM (reads per kilobase per million) distribution for LncRNAs in all PBMCs from IS patients and healthy controls. **(B)** Three-dimensional principal component analysis (PCA) of all 15 samples to evaluate the variability of RNA-seq data. The axes represent the principal components (PC1, PC2, and PC3). **(C--E)** Cluster analysis of differentially expressed LncRNAs and mRNAs of IS patients and healthy controls. **(C)** Hierarchical clustering analysis indicated 3,009 LncRNAs and 3,982 mRNAs that were differentially expressed between IS patients at 24 h (*n* = 5) and healthy controls (*n* = 5), and the number decreased to 2,034 and 1,641 at 7 days, respectively **(D)**. **(E)** The heatmap shows that 73 LncRNAs and 36 mRNAs were differentially expressed between 24 h and 7 days in IS patients. In the color scheme, red indicates higher expression, and green indicates lower expression.](fneur-10-00036-g0001){#F1}

To investigate the key LncRNAs and mRNAs involved in ischemic stroke development, RNA-seq was performed to detect the differentially expressed LncRNAs and genes between ischemic stroke patients and the control group. The EB-Seq algorithm was used to identify the different LncRNAs and coding genes. Lastly, 3,009 LncRNAs were found to be differentially expressed, including 455 upregulated and 2,554 downregulated LncRNAs at 24 h after stroke. Moreover, there were 3,982 differentially expressed mRNAs including 1,750 upregulated and 2,232 downregulated genes. The heatmap is displayed in [Figure 1C](#F1){ref-type="fig"}. However, the numbers of both differentially expressed LncRNAs and genes decreased at 7 days after stroke. There were 2,034 differentially expressed LncRNAs, composed of 1,859 downregulated and 175 upregulated LncRNAs. In addition, 1,641 mRNAs, consisting of 1,028 downregulated and 613 upregulated mRNAs, were detected at 7 days. The differentially expressed LncRNAs and mRNAs are demonstrated as a heatmap ([Figure 1D](#F1){ref-type="fig"}). Comparing IS 24 h and IS 7 days, 73 differentially expressed LncRNAs (55 up- and 18 downregulated) and 36 differentially expressed mRNAs (22 up- and 14 downregulated) were identified, and the heatmap is shown in [Figure 1E](#F1){ref-type="fig"}.

The GO and KEGG Enrichment of Differentially Expressed mRNAs
------------------------------------------------------------

To evaluate the functions of differentially expressed mRNAs, GO and KEGG pathway enrichment analyses were conducted. In the 24 h group, GO analysis was performed on 3,382 significantly dysregulated mRNAs, and the top 20 results are presented in [Figure 2A](#F2){ref-type="fig"}. In the analysis of upregulated mRNAs, 275, 113, and 96 GO terms were significantly enriched in biological process, cell component and molecular function, respectively. In the analysis of downregulated mRNAs, 263, 66, 110 GO terms were significantly enriched in biological process, cell component and molecular function, respectively. Biological processes clustered in transcriptional and translational regulation were the most significantly enriched GO annotations at 24 h after stroke. Similarly, the top 10 results of the KEGG analysis are presented in [Table 4](#T4){ref-type="table"}. KEGG analysis showed that 35 pathways were included in the mRNA upregulation and that 44 pathways related to downregulated mRNAs were significantly enriched. Among these significantly enriched pathways, ribosome and lysine degradation were the most significant pathways ([Table 4](#T4){ref-type="table"}).

![GO enrichment of differentially expressed mRNAs. Significantly enriched Gene Ontology (GO) terms of differentially expressed mRNAs in patients at 24 h **(A)** and 7 days **(B)** after stroke. The y-axis shows GO terms, and the x-axis presents counts of differentially expressed mRNAs in IS patients enriched for GO terms. The color scale represents the --log *P-*value.](fneur-10-00036-g0002){#F2}

###### 

Top 10 significant KEGG pathways for differentially expressed LncRNAs and mRNAs.

  **Term**                                          **Regulation**   **Count**   ***P*****-value**
  ------------------------------------------------- ---------------- ----------- -------------------
  **IS 24h**                                                                     
  Lysine degradation                                Down             17          3.40E-06
  Insulin signaling pathway                         Down             32          4.48E-06
  FoxO signaling pathway                            Down             29          2.44E-05
  Thyroid hormone signaling pathway                 Down             24          0.000
  Adherens junction                                 Down             17          0.000
  Renal cell carcinoma                              Down             16          0.001
  Osteoclast differentiation                        Down             25          0.001
  Neurotrophin signaling pathway                    Down             24          0.002
  mRNA surveillance pathway                         Down             18          0.003
  Prostate cancer                                   Down             17          0.005
  Ribosome                                          Up               72          1.75E-36
  Systemic lupus erythematosus                      Up               71          3.57E-35
  Alcoholism                                        Up               64          2.88E-20
  Oxidative phosphorylation                         Up               47          4.90E-15
  Huntington\'s disease                             Up               52          5.58E-12
  Alzheimer\'s disease                              Up               49          8.57E-12
  Parkinson\'s disease                              Up               42          1.84E-10
  Non-alcoholic fatty liver disease                 Up               38          1.15E-07
  Metabolic pathways                                Up               166         2.40E-06
  Viral carcinogenesis                              Up               43          4.85E-06
  **IS 7d**                                                                      
  Lysine degradation                                Down             9           0.000
  Inflammatory mediator regulation of TRPchannels   Down             12          0.000
  Parkinson\'s disease                              Down             14          0.001
  Melanogenesis                                     Down             11          0.002
  Phototransduction                                 Down             5           0.004
  FoxO signaling pathway                            Down             12          0.005
  beta-Alanine metabolism                           Down             5           0.005
  GABAergic synapse                                 Down             9           0.007
  Oxytocin signaling pathway                        Down             13          0.007
  mRNA surveillance pathway                         Down             9           0.008
  Systemic lupus erythematosus                      Up               26          1.93E-13
  Alcoholism                                        Up               26          1.51E-10
  Ribosome                                          Up               17          1.95E-06
  Alzheimer\'s disease                              Up               19          2.98E-06
  Oxidative phosphorylation                         Up               14          0.000
  Huntington\'s disease                             Up               17          0.000
  Viral carcinogenesis                              Up               18          0.000
  Parkinson\'s disease                              Up               13          0.001
  Transcriptional misregulation in cancer           Up               14          0.003
  p53 signaling pathway                             Up               7           0.007

*KEGG, kyoto encyclopedia of genes and genomes; IS, ischemic stroke*.

For day 7, 1,308 significantly differentially expressed mRNAs were analyzed using the GO database. The top 20 results of the GO analysis are demonstrated in [Figure 2B](#F2){ref-type="fig"}. In the analysis of upregulated mRNAs, 215, 64, and 93 GO terms were significantly enriched in biological process, cell component and molecular function, respectively. In the analysis of downregulated mRNAs, 323, 35, and 134 GO terms were significantly enriched in biological process, cell component and molecular function, respectively. Biological processes clustered in transcriptional regulation and nucleosome assembly were the most significantly enriched GO annotations at 7 days after stroke. Moreover, the top 10 results of the KEGG analysis are shown in [Table 4](#T4){ref-type="table"}. KEGG analysis indicated that 19 pathways were involved in mRNA upregulation and 32 pathways related to downregulated mRNAs were significantly enriched. As expected, ribosome and lysine degradation were among the top 3 significantly enriched pathways ([Table 4](#T4){ref-type="table"}). However, the inflammatory mediator regulation of TRP channels and GABAergic synapses were two specifically downregulated pathways among the top 10 significantly enriched pathways compared with the 24 h group. These data suggested that inflammation might play an important role in the development of ischemic stroke.

Venn Analysis
-------------

We constructed a Venn diagram to further analyze the interactions among differentially expressed LncRNAs. A total of 1,383 and 318 LncRNAs were specifically expressed in ischemic stroke patients after 24 h and 7 days, respectively. In addition, 2,539 and 200 specifically expressed mRNAs in the aforementioned comparison were used to construct a Venn diagram. As shown in [Figures 3A,B](#F3){ref-type="fig"}, 3,135 differentially expressed genes (1,716 LncRNAs and 1,419 mRNAs) were common in the two comparisons.

![Venn analysis. **(A)** Venn diagram showing the number of specific and common LncRNAs expressed in IS 24-h patients vs. healthy controls and IS 7-day patients vs. healthy controls. **(B)** Venn diagram showing the number of specific and common mRNAs expressed in the aforementioned two comparisons. Moreover, the lncRNA-mRNA network was constructed based on the Venn analysis between the differentially expressed LncRNAs and mRNAs. **(C,D)** show the potential relationship between the dysregulated LncRNAs and mRNAs in the IS patients at 24 h and 7 days, respectively. The color key indicates differential gene degrees.](fneur-10-00036-g0003){#F3}

To determine the potential functions of differentially expressed LncRNAs in the Venn diagrams, we predicted the possible targets of these LncRNAs in cis-regulatory relationships. We identified protein-coding genes 10 kb upstream and downstream of the differentially expressed LncRNAs. Comparing the IS 24 h patient and healthy control samples, we found 840 LncRNAs that were transcribed close to (\< 10 kb) 155 protein-coding neighbors. However, only 12 cis-target protein-coding genes were found to be coexpressed with 182 LncRNAs compared between the IS 7 d patient and healthy control samples ([Table 5](#T5){ref-type="table"}). Pathway analysis revealed that several KEGG pathways were related only to the 24 h after ischemic stroke, such as the systemic lupus erythematosus pathway, adherent junction pathway, and tight junction pathway.

###### 

Top 20 differentially expressed LncRNAs and adjacent coexpressed mRNAs.

  ------------------------------------------------------------------------------------------
  **lncRNA**     **Expression**   **FDR**    **Protein-coding gene name**   **Regulation**
  -------------- ---------------- ---------- ------------------------------ ----------------
  **IS 24h**                                                                

  LOC642852      Down             0          POFUT2                         Down

  LOC90784       Down             0          POLR1A                         Down

  RPL10AP8       Down             0          PTCD2                          Down

  FGD5-AS1       Down             0          NR2C2                          Down

  LOC100133091   Down             0          SPDYE16                        Down

  LOC107984305   Down             0          ILK                            Up

  LOC105377303   Down             6.25E-12   PRDM8                          Down

  LOC101060212   Down             8.31E-12   TBC1D3G                        Down

  LOC107984036   Down             1.44E-10   RAB33B                         Down

  LOC105373041   Down             2.19E-10   TP53BP2                        Down

  LOC105371449   Down             5.14E-10   PMVK                           Up

  CCDC58P4       Down             7.19E-10   HIGD1A                         Up

  RPS10P1        Down             4.25E-08   HIST1H2BF/\                    Up/Up
                                             HIST1H4E                       

  AK4P4          Down             5.36E-08   KIAA2026                       Down

  LOC100419838   Down             7.31E-08   ZNF320                         Down

  RPS10P7        Down             9.28E-08   LOC107985246                   Down

  LOC91450       Down             1.15E-07   TBC1D2B                        Down

  SNORA7B        Down             1.18E-07   EFCAB12                        Down

  LOC107984754   Down             2.81E-07   ANKDD1A                        Down

  LOC729867      Down             5.94E-07   PEA15                          Up

  RMRP           Up               0          SIT1                           Up

  SNORA59A       Up               0          VPS13D                         Down

  SCARNA12       Up               0          PHB2/EMG1                      Up/Up

  TEN1-CDK3      Up               5.55E-16   CDK3                           Down

  SNORD32A       Up               5.15E-13   RPL13A                         Up

  ILF3-AS1       Up               7.42E-12   SLC44A2                        Down

  SNORA5A        Up               4.09E-11   TBRG4                          Up

  MIR6732        Up               2.18E-10   ZC3H12A                        Up

  LINC01126      Up               9.07E-10   ZFP36L2                        Down

  SNORA7A        Up               1.97E-08   RPL32                          Up

  THAP7-AS1      Up               2.78E-08   THAP7                          Up

  LOC101929431   Up               3.32E-08   CCDC7                          Up

  SCARNA21       Up               1.06E-07   CHD3                           Down

  RASSF1-AS1     Up               2.34E-07   ZMYND10                        Down

  RPL24P4        Up               3.42E-06   GNMT                           Down

  TMEM191A       Up               1.03E-05   PI4KA                          Down

  EIF4EP2        Up               1.68E-05   PHB                            Up

  B4GALT1-AS1    Up               1.78E-05   B4GALT1                        Down

  FLJ38576       Up               2.43E-05   CYP4V2                         Down

  LOC105371038   Up               6.13E-05   MCRIP2                         Up

  **IS 7d**                                                                 

  RNU6-384P      Down             4.06E-06   LOC107985416                   Down

  LOC105373836   Down             4.50E-05   CFLAR                          Down

  VN2R16P        Down             0.000      ZNF490                         Down

  LOC102724273   Down             0.000      CNOT3                          Down

  PMS2P9         Down             0.000      SPDYE18                        Down

  MIR6740        Down             0.012      ELF3                           Down

  KIR2DP1        Down             0.031      KIR2DL1                        Down

  RNU6-45P       Down             0.042      COX8A                          Up

  AOC4P          Down             0.047      AOC3                           Down

  LOC107984695   Down             0.048      LOC105370706                   Down

  TMPO-AS1       Up               8.03E-05   TMPO                           Up

  LACTB2-AS1     Up               0.015      TRAM1                          Up
  ------------------------------------------------------------------------------------------

*lncRNA, long noncoding RNAs; FDR, false discovery rate; IS, ischemic stroke*.

The Coexpression Network
------------------------

To explore the potential interplay between LncRNAs and mRNAs, we calculated the coexpression association between the dysregulated LncRNAs and their target mRNAs based on the Venn diagrams. In total, 1,312 differentially expressed LncRNAs and 2,539 differentially expressed mRNAs were included in the coexpression network for ischemic stroke patients at 24 h and healthy controls. These differentially expressed genes constructed 3,923 network nodes and 420,593 connections comparing ischemic stroke patients at 24 h and healthy controls. However, comparing ischemic stroke patients at 7 days and healthy controls, the coexpression network profile consisted of 518 network nodes among 301 differentially expressed LncRNAs and 200 differentially expressed mRNAs with 8,185 connections ([Figures 3C,D](#F3){ref-type="fig"}).

Validation of the RNAs
----------------------

To validate our RNA-seq data independently, we randomly selected six differentially expressed LncRNAs and examined their expression patterns in ischemic stroke patients and healthy controls by qPCR. With regard to the upregulated transcripts, RNA-seq appeared to be more sensitive than qPCR. Based on the qPCR results, three LncRNAs (SCARNA10, TERC, LINC01481) exhibited higher expression (*p* \< 0.01), and three LncRNAs (FLJ23867, H3F3AP6, TNPO1P1) exhibited lower expression (*p* \< 0.05) in ischemic stroke patient PBMCs than in healthy control PBMCs. As shown in [Figure 4](#F4){ref-type="fig"}, the qPCR results for all of the evaluated LncRNAs probes were concordant with the RNA-seq data. This agreement confirmed the accuracy of the RNA-seq results.

![Validation of the selected LncRNAs. The verification of 6 randomly selected LncRNAs from IS patients and healthy controls by quantitative real-time PCR (qRT-PCR). Column heights represent mean fold changes in expression of the IS group. The trends in the expression of randomly selected LncRNAs detected by qRT-PCR (*p* \< 0.05 vs. control) were similar to those detected by RNA-seq.](fneur-10-00036-g0004){#F4}

Discussion {#s4}
==========

This is the first prospective study to demonstrate longitudinal changes in the expression of LncRNAs in human blood following acute ischemic stroke. A specific set of LncRNAs was observed to change expression over time. Notably, we found that the level of LncRNAs in the pathway of antigen processing and presentation was clearly upregulated at 24 h and had recovered to normal levels on day 7 after stroke. Moreover, inflammatory mediator regulation of TRP channels and GABAergic synapses were two specifically downregulated pathways on day 7 after stroke. These two signaling pathways are both related to inflammatory action. Their decrease may indicate the end of the inflammatory process. Our research proved the dynamic changes in the peripheral immune system after ischemic stroke at the gene level, suggesting that LncRNA might be included with mRNA and miRNA as possible biomarkers for further exploration of stroke immune system changes and causes.

Appreciation for the role of LncRNAs in the regulation of the pathophysiologic processes of ischemic stroke has increased. Although LncRNAs are usually not translated into proteins, they take part in the regulation of protein-coding genes and related signaling pathways involved in the development of multiple diseases ([@B6]). According to previous studies, aberrant expression of LncRNAs was observed in PBMCs from ischemic stroke patients using oligonucleotide microarrays ([@B19]). Through RNA-seq technology, this study demonstrated an altered gene expression profile in PBMCs during acute ischemic stroke as well. In addition, we investigated whether the expression of LncRNAs in PBMCs changed over time by serially drawing blood from every subject. Using microarray analysis, Dykstra-Aiello et al. found that 299 and 97 LncRNAs were differentially expressed in whole-blood RNA samples from male and female Canadian stroke patients, respectively, over a wide range of time points (4.4--156.0 h) ([@B4]). Similarly, by using high-throughput technologies, our study revealed that the expression levels of LncRNAs were altered in ischemic stroke patients in a Chinese Han population. Compared to microarrays, RNA-seq analysis provides a more comprehensive coverage of whole transcriptomes. As a result, we found 3,009 LncRNAs and 3,982 mRNAs that were differentially expressed in the PBMCs of patients at 24 h after stroke. On the 7th day, the number of differentially expressed LncRNAs and mRNAs decreased to 2,034 and 1,641, respectively. The expression of LncRNAs suggested an increase in stroke risk in both studies. Especially in this study, we found that the level of LncRNAs in the pathway of antigen processing and presentation was upregulated at 24 h and the level of LncRNAs in TRP and GABAergic synapses were downregulated on day 7 after stroke.

Pathway analysis showed that genes participating in the intestinal immune network for IgA production were significantly upregulated 24 h after stroke. An animal study of the intestinal flora proved that intestinal dysbiosis ameliorated ischemic brain injury through an increase in regulatory T cells and a reduction in IL-17^+^γδ T cells ([@B20]). Again, the LncRNA levels related to the pathway of the intestinal immune network for IgA production decreased to normal at day 7 in this study. Although the underlying signaling process that results in widespread immunosuppression after stroke is not well-understood, this result suggested that LncRNA may be part of the process. To provide another hope for treatment of systemic infections following immunosuppression, this result needs to be prospectively confirmed in patients with infection after stroke.

A strength of the study is the homogenous stroke population that included moderate-to-severe acute ischemic stroke subjects with anterior or middle cerebral artery occlusion presenting within 4.5--24 h of symptom onset. This study also used samples with assigned blood draw times (24 h and 7 days after stroke).

The sample size of this study was small, which may have limited our ability to identify differences between groups. In addition, evaluation of multiple genes as performed in the data analysis of RNA-seq would increase the risk of false discovery. Although correction for multiple comparisons was performed and six differentially expressed LncRNAs were validated by qPCR in this study, confirmation by an independent study is required.

In conclusion, we explored for the first time that ischemic stroke can influence the expression of LncRNAs and mRNAs in human PBMCs. GO and KEGG pathway analyses revealed that peripheral immunity may participate in the brain injury of acute ischemic stroke. Our results provide a framework for further study on the role of LncRNAs in peripheral immune system changes following ischemic stroke.
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